Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash from Operations data on file, last reported at 18750000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 22.89% year-over-year to 18750000.0 in Q1 2026; TTM through Mar 2026 was 63558000.0, a 913.91% decrease from a year earlier, with the FY2025 full-year figure at 60065000.0, down 2608.07% from the prior year.
• Cash from Operations for Q1 2026 stood at 18750000.0, down from 16798000.0 in the prior quarter.
• Over the last five years, Cash from Operations for FULC reached as high as 58899000.0 in Q2 2024 and fell as low as 27882000.0 in Q3 2022.
• Historically, Cash from Operations has averaged 15826352.94 across 5 years, with a median of 19696000.0 in 2022.
• Across the five-year window, Cash from Operations soared 383.37% in 2024 and sank 123.46% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 19696000.0 in 2022, then dropped by 17.58% to 23158000.0 in 2023, then rose by 27.62% to 16761000.0 in 2024, then retreated by 0.22% to 16798000.0 in 2025, then retreated by 11.62% to 18750000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 18750000.0 in Q1 2026, 16798000.0 in Q4 2025, and 14190000.0 in Q3 2025.